Skip to main content
SpringerLink
Log in

A ten-year comparison of treatment and outcomes of cancer-associated thrombosis to non-cancer venous thromboembolism: from traditional anticoagulants to direct oral anticoagulants

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

DOACs have emerged as first-line treatment in most cancer-associated thrombosis (CAT), representing a paradigm shift in its management. However, CAT management remains challenging and requires careful risk–benefit considerations. A retrospective analysis of CAT presentations to a tertiary referral centre from January 2011 to December 2020. Outcomes in CAT patients were compared to VTE patients without malignancy. Subgroup analysis was also conducted for CAT according to anticoagulation type. 514 CAT cases from 491 patients were identified from 3230 total VTE cases. CAT patients had higher rates of major VTE (PE and/or proximal DVT) compared to patients without malignancy (78.4% vs. 66.8%, p < 0.001). CAT patients also had higher rates of VTE recurrence (HR 1.66, 95%CI 1.23–2.26), major bleeding (HR 3.41, 95%CI 2.36–4.93), VTE-related mortality (HR 2.59, 95%CI 1.46–4.62) and bleeding-related mortality (HR 2.66, 95%CI 1.05–6.73). There were no significant differences in rates of VTE recurrence, major bleeding, VTE-related mortality or fatal bleeding between CAT patients treated with DOACs, enoxaparin or warfarin. In the subgroup of CAT treated with DOACs, there was no significant difference in rates of GI bleeding compared to the enoxaparin subgroup (HR 0.17, 95%CI 0.02–1.26). CAT was associated with a larger clot burden and higher rates of VTE recurrence, major bleeding and mortality compared to VTE patients without malignancy in this large real-world study. This study demonstrated no significant differences in complication rates for CAT patients treated with DOACs over enoxaparin, suggesting that DOACs can be safely used in most cases of CAT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122(10):1712–1723

    Article  CAS  PubMed  Google Scholar 

  2. Mahajan A, Brunson A, Adesina O, Keegan THM, Wun T (2022) The incidence of cancer-associated thrombosis is increasing over time. Blood Adv 6(1):307–320

    Article  PubMed  PubMed Central  Google Scholar 

  3. Fernandes CJ, Morinaga LTK, Alves JL, Castro MA, Calderaro D, Jardim CVP et al (2019) Cancer-associated thrombosis: the when, how and why. Eur Respir Rev 28(151):180119

    Article  PubMed  PubMed Central  Google Scholar 

  4. Samuelson Bannow BT, Lee A, Khorana AA, Zwicker JI, Noble S, Ay C et al (2018) Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost 16(6):1246–1249

    Article  CAS  PubMed  Google Scholar 

  5. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM et al (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382(17):1599–1607

    Article  CAS  PubMed  Google Scholar 

  6. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight Heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017–2023

    Article  CAS  PubMed  Google Scholar 

  7. (2013) Edoxaban versus Warfarin for the treatment of symptomatic venous thromboembolism. New Engl J Med 369(15):1406–1415

  8. Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C et al (2022) 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 23(7):e334–e347

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Khorana AA, Noble S, Lee AYY, Soff G, Meyer G, O’Connell C et al (2018) Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 16(9):1891–1894

    Article  CAS  PubMed  Google Scholar 

  10. Kahale LA, Hakoum MB, Tsolakian IG, Alturki F, Matar CF, Terrenato I et al (2018) Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006650.pub5

    Article  PubMed  PubMed Central  Google Scholar 

  11. Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF et al (2015) Tinzaparin vs Warfarin for treatment of acute venous thromboembolism in patients with active cancer. JAMA 314(7):677

    Article  CAS  PubMed  Google Scholar 

  12. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M et al (2003) Low-molecular-weight Heparin versus a Coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146–153

    Article  CAS  PubMed  Google Scholar 

  13. World Health Organisation (2019) International Statistical Classification of Diseases and Related Health Problems 10th Revision. ICD-10

  14. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13(11):2119–2126

    Article  CAS  PubMed  Google Scholar 

  15. Khorana AA, Dalal M, Lin J, Connolly GC (2013) Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 119(3):648–655

    Article  CAS  PubMed  Google Scholar 

  16. Mulder FI, Horváth-Puhó E, van Es N, van Laarhoven HWM, Pedersen L, Moik F et al (2021) Venous thromboembolism in cancer patients: a population-based cohort study. Blood 137(14):1959–1969

    Article  CAS  PubMed  Google Scholar 

  17. Faiz AS, Khan I, Beckman MG, Bockenstedt P, Heit JA, Kulkarni R et al (2015) Characteristics and risk factors of cancer associated venous thromboembolism. Thromb Res 136(3):535–541

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Monreal M, Falga C, Valdes M, Suarez C, Gabriel F, Tolosa C et al (2006) Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 4(9):1950–1956

    Article  CAS  PubMed  Google Scholar 

  19. Blom JW (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293(6):715

    Article  CAS  PubMed  Google Scholar 

  20. Puurunen MK, Gona PN, Larson MG, Murabito JM, Magnani JW, O’Donnell CJ (2016) Epidemiology of venous thromboembolism in the Framingham Heart Study. Thromb Res 145:27–33

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Turpie A, Haas S, Weitz J, Ageno W, Angchaisuksiri P, Bounameaux H et al (2017) GARFIELD-VTE: 6-month outcomes. Res Pract Thromb Haemost 1:1–15

    Google Scholar 

  22. Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M (2013) Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res. 131(1):24–30

    Article  CAS  PubMed  Google Scholar 

  23. Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana A et al (2016) International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 17:452–466

    Article  Google Scholar 

  24. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H et al (2016) Antithrombotic therapy for VTE disease. Chest 149(2):315–352

    Article  PubMed  Google Scholar 

  25. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI et al (2015) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. J Clin Oncol 33(6):654–656

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. McBane RD, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A et al (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 18(2):411–421

    Article  CAS  PubMed  Google Scholar 

  27. El MM, Hassan A, Algaby AZ (2021) Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular 29(5):745–750

    Article  CAS  PubMed  Google Scholar 

  28. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615–624

    Article  CAS  PubMed  Google Scholar 

  29. Planquette B, Bertoletti L, Charles-Nelson A, Laporte S, Grange C, Mahé I et al (2022) Rivaroxaban vs dalteparin in cancer-associated thromboembolism. Chest 161(3):781–790

    Article  CAS  PubMed  Google Scholar 

  30. Coleman CI, Caroti KS, Abdelgawwad K, Psaroudakis G, Fatoba S, Rivera M et al (2023) Effectiveness and safety of Rivaroxaban and low molecular weight heparin in cancer-associated venous thromboembolism. JACC CardioOncol 5(2):189–200

    Article  PubMed  PubMed Central  Google Scholar 

  31. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI et al (2023) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 41(16):3063–3071

    Article  CAS  PubMed  Google Scholar 

  32. Li A, Garcia DA, Lyman GH, Carrier M (2019) Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res 173:158–163

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NorthErn Clinical Diagnostics and ThrombovAscular Research (NECTAR) Centre, Northern Health, 185 Cooper St, Epping, VIC, 3076, Australia

    Benjamin Wee, Jeffrey Lai, Zille Khattak, Anna Kwok, Prahlad Ho, Hui Yin Lim & Brandon Lui

  2. Department of Pharmacy, Northern Health, Epping, VIC, Australia

    Cynthia Donarelli

  3. Department of Medicine (Northern Health), University of Melbourne, Heidelberg, VIC, Australia

    Prahlad Ho & Hui Yin Lim

Authors
  1. Benjamin Wee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zille Khattak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anna Kwok
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cynthia Donarelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Prahlad Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hui Yin Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Brandon Lui
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin Wee.

Ethics declarations

Conflict of interest

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wee, B., Lai, J., Khattak, Z. et al. A ten-year comparison of treatment and outcomes of cancer-associated thrombosis to non-cancer venous thromboembolism: from traditional anticoagulants to direct oral anticoagulants. J Thromb Thrombolysis 57, 658–667 (2024). https://doi.org/10.1007/s11239-023-02943-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-023-02943-2

Keywords

Search

Navigation